Michael Kaseta Sells 1,091 Shares of Liquidia Co. (NASDAQ:LQDA) Stock

Liquidia Co. (NASDAQ:LQDA) CFO Michael Kaseta sold 1,091 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $11.51, for a total value of $12,557.41. Following the transaction, the chief financial officer now directly owns 312,328 shares of the company’s stock, valued at $3,594,895.28. This trade represents a 0.35 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Michael Kaseta also recently made the following trade(s):

• On Monday, October 14th, Michael Kaseta sold 3,892 shares of Liquidia stock. The shares were sold at an average price of $11.11, for a total value of $43,240.12.

Liquidia Trading Up 0.3 %

NASDAQ LQDA traded up $0.03 on Tuesday, reaching $11.26. The company had a trading volume of 1,423,986 shares, compared to its average volume of 972,832. Liquidia Co. has a 52 week low of $6.83 and a 52 week high of $16.99. The stock’s 50 day moving average is $10.76 and its 200-day moving average is $11.34.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Scotiabank began coverage on Liquidia in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 target price for the company. BTIG Research dropped their target price on shares of Liquidia from $29.00 to $25.00 and set a “buy” rating on the stock in a report on Monday, August 19th. Lifesci Capital began coverage on shares of Liquidia in a research note on Thursday, October 3rd. They set an “outperform” rating and a $30.00 target price for the company. HC Wainwright restated a “buy” rating and set a $29.00 price objective on shares of Liquidia in a report on Thursday, November 14th. Finally, Bank of America reduced their target price on shares of Liquidia from $24.00 to $23.00 and set a “buy” rating on the stock in a research note on Tuesday, August 20th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $24.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Quest Partners LLC bought a new position in Liquidia in the second quarter valued at approximately $27,000. Hilltop National Bank acquired a new stake in shares of Liquidia in the 2nd quarter valued at approximately $33,000. Clear Harbor Asset Management LLC bought a new position in shares of Liquidia in the third quarter valued at $100,000. Signaturefd LLC raised its position in Liquidia by 38,400.0% during the third quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock worth $100,000 after acquiring an additional 9,984 shares in the last quarter. Finally, Ballentine Partners LLC bought a new position in shares of Liquidia in the 3rd quarter valued at about $110,000. Institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).